Bristol-Myers Squibb: Leukemia, Lymphocytic, Chronic, B-Cell trials

The registry lists 24 Leukemia, Lymphocytic, Chronic, B-Cell studies with Bristol-Myers Squibb as lead sponsor. 1 are open to participants now and 5 have results posted.

Phase 1 15Phase 2 5Phase 3 3No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing SettingRecruitingNCT06788639
• A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT02733042Phase 1/2Results posted
• A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT02406742Phase 1/2Results posted
• Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaCompletedNCT00963105Phase 2Results posted
• Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)CompletedNCT00910910Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line TherapyCompletedNCT00774345Phase 3Results posted
• A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i TherapiesWithdrawnNCT06205290Phase 3
• A Rollover Study of CC-122Active, not recruitingNCT05688475Phase 1
• A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedNCT05244070Phase 1
• A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT04434196Phase 1
• Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell ProductTerminatedNCT03436771
• Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)Active, not recruitingNCT03331198Phase 1/2
• A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic NeoplasmsCompletedNCT02842229
• Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT01744626Phase 1
• Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic LymphomaCompletedNCT01732861Phase 1
• Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.CompletedNCT01353625Phase 1
• Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's MacroglobulinemiaCompletedNCT01351935Phase 1
• First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell CancersCompletedNCT01120457Phase 1
• Connect™ CLL: The Chronic Lymphocytic Leukemia Disease RegistryCompletedNCT01081015
• Study of Dasatinib and Bendamustine in Chronic Lymphocytic LeukemiaWithdrawnNCT00872976Phase 1
• Study of MDX-1411 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Mantle Cell LymphomaWithdrawnNCT00730652Phase 1
• Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL)CompletedNCT00593944Phase 1
• A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic LeukemiaCompletedNCT00431873Phase 2
• A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic LeukemiaCompletedNCT00419250Phase 1